Kainos Medicine Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • PIPE

  • Latest Deal Amount
  • $9.9M

  • Investors
  • 10

Kainos Medicine General Information

Description

Developer of novel drugs designed to advance treatments for cancer, brain, and infectious diseases. The company offers a diverse pipeline, including compounds in clinical trials for Parkinson's disease and HIV/AIDS, enabling businesses to access therapies for complex and underserved conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 3rd Floor, Building. A, Korea Bio-Park
  • 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 3rd Floor, Building. A, Korea Bio-Park
  • 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82

Kainos Medicine Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kainos Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. PIPE 05-Jan-2026 $9.9M Completed Generating Revenue
18. PIPE 21-Mar-2025 Completed Generating Revenue
17. PIPE 10-Jun-2024 Completed Generating Revenue
16. PIPE 23-Jun-2022 Completed Generating Revenue
15. PIPE 11-Nov-2021 Completed Generating Revenue
14. PIPE 01-Jan-2021 Completed Generating Revenue
13. PIPE 09-Aug-2019 Completed Generating Revenue
12. PIPE 30-Aug-2018 Completed Generating Revenue
11. PIPE 16-May-2018 $4.75M $11.5M Completed Generating Revenue
10. PIPE 22-Dec-2017 $4.25M $6.74M Completed Generating Revenue
To view Kainos Medicine’s complete valuation and funding history, request access »

Kainos Medicine Patents

Kainos Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026054314-A1 Novel polynucleotide encoding faf1 protein and faf1 protein variant Pending 06-Sep-2024
JP-2025533331-A Cell line for producing faf1 exosomes at high yield and method for preparing same Pending 29-Sep-2022
AU-2023350542-A1 Cell line for producing faf1 exosomes in high yield, and preparation method therefor Active 29-Sep-2022
AU-2023350542-B2 Cell line for producing faf1 exosomes in high yield, and preparation method therefor Active 29-Sep-2022
EP-4596699-A1 Cell line for producing faf1 exosomes in high yield, and preparation method therefor Pending 29-Sep-2022 C12N15/85
To view Kainos Medicine’s complete patent history, request access »

Kainos Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kainos Medicine Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Axis Investment Venture Capital Minority
Magna Investment (Seoul) Venture Capital Minority
DreamStone Private Equity PE/Buyout Minority
NH Investment & Securities Investment Bank Minority
Alphaview Corporation Minority
You’re viewing 5 of 10 investors. Get the full list »

Kainos Medicine Investments & Acquisitions (2)

Kainos Medicine’s most recent deal was a Early Stage VC with FAScinate Therapeutics for . The deal was made on 01-Aug-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
FAScinate Therapeutics 01-Aug-2020 Early Stage VC Drug Discovery
Hana Financial Eleventh Special Purpose Acquisition 08-Jun-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Kainos Medicine’s complete investments and acquisitions history, request access »

Kainos Medicine FAQs

  • When was Kainos Medicine founded?

    Kainos Medicine was founded in 2007.

  • Where is Kainos Medicine headquartered?

    Kainos Medicine is headquartered in Seongnam, South Korea.

  • What is the size of Kainos Medicine?

    Kainos Medicine has 25 total employees.

  • What industry is Kainos Medicine in?

    Kainos Medicine’s primary industry is Biotechnology.

  • Is Kainos Medicine a private or public company?

    Kainos Medicine is a Private company.

  • What is Kainos Medicine’s current revenue?

    The current revenue for Kainos Medicine is .

  • How much funding has Kainos Medicine raised over time?

    Kainos Medicine has raised $34.6M.

  • Who are Kainos Medicine’s investors?

    Axis Investment, Magna Investment (Seoul), DreamStone Private Equity, NH Investment & Securities, and Alphaview are 5 of 10 investors who have invested in Kainos Medicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process